Dysregulated gene expression of extracellular matrix and adhesion molecules in saphenous vein conduits of hemodialysis patients  by Sun, Yongxin et al.
EVOLVING TECHNOLOGY/BASIC SCIENCE
E
T
/B
SDysregulated gene expression of extracellular matrix and adhesion
molecules in saphenous vein conduits of hemodialysis patientsYongxin Sun, MD,a Wenjun Ding, MD,a QiangWei, MD,a Zhenya Shen, MD,b and ChunshengWang, MDaFrom th
Shang
of So
Support
2D00
Disclosu
Yongxin
Receive
public
Address
shan
(E-ma
0022-52
Copyrig
doi:10.1
684Objective: The incidence of cardiovascular disease was approximately 10 times higher in hemodialysis patients
with end-stage renal disease than in the general population. The saphenous vein is the most commonly used con-
duit for coronary artery bypass grafting. However, the extracellular matrix and adhesion molecule characteristics
of saphenous vein in hemodialysis patients remain unclear. The aim of the present study was to survey the ex-
tracellular matrix gene expression profile of the saphenous vein in hemodialysis patients undergoing coronary
artery bypass grafting.
Methods: A total of 34 patients undergoing elective coronary artery bypass grafting were enrolled. Of the 34
patients, 15 with end-stage renal disease required maintenance hemodialysis. The control group consisted of
the other 19 patients without preoperative renal disease. Samples of the saphenous vein were obtained at coro-
nary artery bypass grafting. The expression profile of the extracellular matrix genes was analyzed by microarray.
The tissue matrix metallopeptidase/tissue inhibitor of metallopeptidase protein activities in the saphenous vein
were evaluated by immunocytochemistry and Western blotting.
Results: Nineteen extracellular matrix and adhesion molecule-focused genes demonstrated at least a threefold
difference in expression between the 2 groups. Upregulation was observed in 16 genes, and 3 genes appeared to
be downregulated. Notable imbalanced matrix metallopeptidase/tissue inhibitor of metallopeptidase protein ac-
tivities of saphenous vein exposed to end-stage renal disease conditions was found.
Conclusions: The results from present study suggest that the native extracellular matrix gene expression profile
of the saphenous vein conduits in hemodialysis patients show signs of the vein graft disease process before
coronary surgery. Furthermore, some preoperative profiles of hemodialysis patients undergoing coronary artery
bypass grafting might provide some useful clues regarding vein graft quality and prompt adjustment in surgical
strategy. (J Thorac Cardiovasc Surg 2012;144:684-9)The incidence of cardiovascular disease is approximately 10
times greater in hemodialysis (HD) patients with end-stage
renal disease (ESRD) than in the general population.1More-
over, the cardiovascular death rates in HD patients are also
greatly increased compared with those in the general popu-
lation.2-4 Although percutaneous coronary intervention
has made significant inroads in the revascularization of
patients with coronary artery disease, some HD patients
still do significantly better in terms of survival and
a reduced need for additional intervention with coronary
artery bypass grafting (CABG).5 The saphenous vein (SV)
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The Journal of Thoracic and Cardiovascular Surg10 years, vein graft occlusive disease occurs in nearly one
half of the conduits.6,7 Vein graft failure occurs secondary
to the deposition of extracellular matrix (ECM).8-10
However, to date, no studies have been published on the
identification and understanding of the ECM and adhesion
molecule characteristics of SV conduits in HD patients.
The aims of the present study were, therefore, to survey
the gene expression profile of the ECM and adhesion
molecules in SV conduits of HD patients undergoing
CABG using microarray technology.METHODS
Study Subjects
For the present study, 34 patients with coronary artery disease undergo-
ing elective CABG at our institutewere enrolled. All these subjects fulfilled
the inclusion criteria and agreed to participate. The local research ethics
committee approved study, and each patient gavewritten informed consent.
Of the 34 subjects, 15 with ESRD were receiving maintenance HD. The
non-HD (control) group included the other 19 patients who had no
preoperative history of renal disease. All patients were receiving conven-
tional anti-angina therapy. The HD sessions were performed 3 times for
4 hr/wk using polysulphone membrane dialysers. The exclusion criteria
were any inflammatory, infective disease, overt clinical heart failure,
neoplastic disease, or acute coronary event during the previous 2 months.
The patients previously diagnosed with diabetes mellitus (fasting glucose
>5.5 mmol/L), hyperlipidemia (total cholesterol level>5.2 mmol/L), or
hypertension (systolic blood pressure >140 mm Hg, diastolic bloodery c September 2012
TABLE 1. Demographics of studied population
Demographic
HD group
(n ¼ 15)
Control group
(n ¼ 19)
P
value
Gender (male) 11 (73.3%) 15 (78.9%) .39
Age (yr) 62.6  10.3 60.1  15.5 .44
Body weight (kg) 66.2  10.6 68.5  13.7 .41
History of smoking (n) 6 (40.0%) 8 (42.1%) .38
History of MI (n) 4 (26.7%) 4 (21.1%) .23
Previous PCI (n) 9 (60.0%) 11 (57.9%) .29
Hypertension (n) 8 (53.3%) 8 (42.1%) .12
Diabetic mellitus (n) 5 (33.3%) 6 (31.5%) .34
Cerebral vessel disease (n) 5 (33.3%) 4 (21.1%) .07
Peripheral vascular disease (n) 5 (33.3%) 4 (21.1%) .09
Duration of HD (yr) 2.2  0.9
Total cholesterol
level (mmol/L)
5.80  2.25 5.04  1.46 .14
Lipoprotein(a) (mg/L) 721.0  253.6 267.3  119.8 <.01
Apolipoprotein A (g/L) 2.48  1.13 1.39  0.84 .04
Apolipoprotein B (g/L) 3.09  1.54 1.67  0.92 <.01
Calcium concentration
(mmol/L)
2.64  1.31 2.25  0.77 .20
Phosphorus concentration
(mmol/L)
2.77  0.86 1.05  0.24 <.01
Calcium 3 phosphorus product 55.74  13.08 35.16  4.31 <.01
PTH (ng/L) 509.6  313.6 80.5  44.7 <.01
Homocysteine (mmol/L) 37.6  10.9 18.8  6.5 .02
IMT in carotid arteries (mm) 1.46  0.32 0.90  0.14 <.01
Coronary artery calcification
score
695.0  126.8 507.3  88.2 .03
HD, Hemodialysis;MI, myocardial infarction; PCI, percutaneous coronary interven-
tion; PTH, parathyroid hormone; IMT, intima-media thickness.
Abbreviations and Acronyms
ECM ¼ extracellular matrix
ESRD ¼ end-stage renal disease
CABG ¼ coronary artery bypass grafting
HD ¼ hemodialysis
SV ¼ saphenous vein
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Spressure>90 mm Hg) were receiving appropriate glucose, lipid-lowering,
or hypertension treatment. The individual characteristics of the patients are
listed in Table 1.
Tissue Samples and RNA Extraction
Samples of the SV were obtained at CABG. Segments of a fewmillime-
ters from the SV were isolated and immediately put into RNAlater
(Ambion, Austin, Tex) for storage at80C. Total RNA extraction was per-
formed using the RNeasy Mini kit (Qiagen, Valencia, Calif) according to
the manufacturer’s instructions. Next, 1 to 2.0 mg of total RNAwas reverse
transcribed into single strand cDNA using MuLV reverse transcriptase
(Applied Biosystems, Foster City, Calif).
cDNA Gene Expression Array Analysis
The expression profile of extracellular matrix and adhesion molecules
genes was analyzed using the RT2 Profiler PCR Array Human Extracel-
lular Matrix and Adhesion Molecules (PAHS-013A; SuperArray Biosci-
ence, Frederick, Md). The results were analyzed using ScanAlyze and
GEArray Analyzer (SuperArray Bioscience).
Immunocytochemistry Evaluation of MMP-2,
MMP-9, TIMP-2, and TIMP-3 Activity in SV of HD
and Control Groups
Theoptimal dilutions for each primary antibody (SantaCruzBiotechnol-
ogy, Santa Cruz, Calif) were found. The sections were incubated with goat
anti-mouse biotinylated second antibody IgGs (Beijing Zhongshan,
Beijing, China). Semiquantitative evaluation was performed by
computer-assisted image analysis (Chengdu Taimeng, Sichuan, China).
Western Blot Analysis of Tissue MMP-2, MMP-9,
TIMP-2, and TIMP-3 Levels
Total protein was fractionated and transferred to polyvinylidene difluor-
ide membranes (Millipore, Bedford, Mass). Each membranewas incubated
with specific antibodies (Calbiochem, SanDiego, Calif) with secondary an-
tibody (Jackson Immunolab, West Grove, Pa). Immune complexes were vi-
sualized with the enhanced chemiluminescence detection system
(Amersham, Piscataway, NJ).
Statistical Analysis
All values are expressed as the mean  standard deviation. Quantita-
tive reverse transcriptase-polymerase chain reaction results are reported
as the relative gene expression, and the x-fold change in target genes was
determined using the 2-DDCt method, as previously described.
11 To eval-
uate the gene expression profile in the HD group, the x-fold change was
determined as (Ct HDCt Actin)(Ct ControlCt Actin). The group compar-
isons were performed using the Student t test. Univariate and multivariate
linear regression analyses (Cox regression model) were performed to
analyze the extent of matrix metallopeptidase-2/tissue inhibitor of
metallopeptidase-2 (MMP-2/TIMP-2) imbalance in relation to the preop-
erative variables.The Journal of Thoracic and CaRESULTS
Demographic Patient Characteristics
The demographics of the population studied did not differ
between the HD and control groups, except for the param-
eters related to ESRD. The 2 groups were well matched
for age, gender, and presentation profile (Table 1).Dysregulated Expression of Gene Profiles
Using the RT2 Profiler PCR Array Human Extracellu-
lar Matrix and Adhesion Molecules (SuperArray Biosci-
ence), we examined the gene expression profile and
compared the relative expression of ECM and adhesion
molecule genes in SV between the HD and control groups.
Of the 84 ECM and adhesion molecule-focused genes in
this microarray, 19 genes demonstrated at least a threefold
difference in expression between the HD and control
groups. Upregulation was observed in 16 genes, and 3 genes
appeared to be downregulated (Table 2). The extent of
MMP-2/TIMP-2 imbalance was calculated with the x-fold
changes of the genes. The extent of MMP-2/TIMP-2 imbal-
ance of the SV in the HD group appeared significantly in-
creased compared with the normal control veins (4.57 
1.24 vs 0.84  0.29, P<.05). Univariate and multivariaterdiovascular Surgery c Volume 144, Number 3 685
TABLE 2. ECM-related genes regulated in saphenous vein of
hemodialysis patients compared with control group*
Symbol Description
x-Fold
difference
P
value
CDH1 Cadherin 1, type 1, E-cadherin 23.83  11.09 <.001
COL12A1 Collagen, type XII, alpha 1 6.74  2.25 .003
COL16A1 Collagen, type XVI, alpha 1 5.61  2.06 .005
COL1A1 Collagen, type I, alpha 1 3.29  1.44 .011
ITGA3 Integrin, alpha 3 4.15  1.63 .008
MMP1 Matrix metallopeptidase 1 8.15  3.80 .001
MMP2 Matrix metallopeptidase 2 19.93  11.75 <.001
MMP12 Matrix metallopeptidase 12 13.00  13.55 <.001
MMP13 Matrix metallopeptidase 13 6.76  2.59 .003
MMP3 Matrix metallopeptidase 3 10.85  9.06 <.001
MMP7 Matrix metallopeptidase 7 15.51  38.62 <.001
MMP8 Matrix metallopeptidase 8 17.91  30.58 <.001
MMP9 Matrix metallopeptidase 9 19.36  5.50 <.001
SGCE Sarcoglycan, epsilon 28.91  13.40 <.001
THBS1 Thrombospondin 1 15.30  6.93 <.001
TIMP1 Tissue metallopeptidase inhibitor 1 4.60  0.58 .007
TIMP2 Tissue metallopeptidase inhibitor 2 3.58  0.96 .009
TIMP3 Tissue metallopeptidase inhibitor 3 11.30  4.38 <.001
TNC Tenascin C 7.81  2.01 .002
x-Fold change for each gene from HD group to control group calculated as 2DDCt.
Among 84 genes analyzed, 16 genes were upregulated>3.0-fold, and 3 were down-
regulated in SV conduits of HD patients. ECM, Extracellular membrane; HD, hemo-
dialysis; SV, saphenous vein. *Gene expression changes 3.0-fold versus control in
RNA level.
TABLE 3. Univariate linear regression analysis of ESRD-related
parameters in relation to MMP-2/TIMP-2 imbalance of SV conduits
Variable
Odds
ratio
95% Confidence
interval
P
value
Gender (male vs female) 1.247 0.48–2.6 .93
Age 1.004 0.97–1.09 .81
Body weight 1.005 0.96–1.04 .08
Hypertension 0.69 0.073–2.88 .26
Hyperlipidemia 0.55 0.084–2.51 .89
Cerebral vessel disease 1.83 0.042–2.05 .10
Periphery vessel disease 1.66 0.105–2.79 .14
Diabetic mellitus 1.902 0.73–3.68 .09
Total cholesterol level 1.57 0.048–2.39 .10
Lipoprotein(a) 3.19 1.92–4.08 .03
Apolipoprotein A 1.17 0.54–1.85 .15
Apolipoprotein B 4.48 1.77–15.49 .02
Calcium concentration 0.66 0.19–1.31 .17
Phosphorus concentration 0.42 0.051–1.65 .11
Calcium 3 phosphorus product 0.93 0.063–1.82 .14
PTH 0.55 0.041–1.07 .19
Homocysteine 1.038 0.96–1.54 .08
IMT in carotid arteries 7.05 2.041–8.07 .01
Coronary artery calcification score 6.49 1.56–7.13 .04
ESRD, End-stage renal disease; MMP, matrix metallopeptidase; TIMP, tissue metal-
lopeptidase inhibitor; SV, saphenous vein; PTH, parathyroid hormone; IMT, intima-
media thickness.
TABLE 4. Multivariate linear regression analysis of ESRD-related
parameters in relation to MMP-2/TIMP-2 imbalance of SV conduits
Variable
Odds
ratio
95% Confidence
interval
P
value
IMT in carotid arteries 16.43 2.02–18.37 <.01
Coronary artery calcification score 5.57 1.32–7.59 .01
ESRD, End-stage renal disease; MMP, matrix metallopeptidase; SV, saphenous vein;
IMT, intima-media thickness.
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Slinear regression analyses showed that the extent of MMP-
2/TIMP-2 imbalance of the SV was directly related to some
preoperative ESRD-related parameters (Tables 3 and 4).
Changed Activities of MMP-2, MMP-9, TIMP-2 and
TIMP-3 in SV of HD Group
A semiquantitative analysis showed that the MMP-2 and
MMP-9 levels in the SVof the HD group (grade, 2.6  0.5
and 1.8  0.4, respectively) were significantly greater than
those in the normal SV (grade, 0.7  0.16 and 0.6  0.15;
P<.01 and P<.02, respectively). TIMP-2 and TIMP-3 im-
munostaining were notably reduced in the SV of the HD
group compared with those in the control group (grade,
0.6  0.19 vs 2.2  0.3 and 0.9  0.28 vs 2.4  0.7;
P<.05 and P<.05, respectively). Figure 1 shows the results
of the immunocytochemistry evaluation.
Alteration of Tissue MMP-2, MMP-9, TIMP-2 and
TIMP-3 Protein Levels Induced by ESRD
The SVexposed to ESRD conditions demonstrated a no-
table increase in MMP-2 and MMP-9 protein levels com-
pared with the normal SV (1.48  0.33 vs 0.92  0.16
densitometry unit and 1.72 0.49 vs 0.98 0.22 densitom-
etry unit, P<.05 and P<.05, respectively). In contrast, the
TIMP-2 and TIMP-3 protein levels in the SV of the HD
group were significantly decreased compared with that in
the normal control veins (66.3  15.8 vs 119.4  20.1686 The Journal of Thoracic and Cardiovascular Surgdensitometry unit and 73.7 11.6 vs 98.5 18.2 densitom-
etry unit, P<.05 and P<.05, respectively). Figure 2 dis-
plays the results from the Western blotting analysis.DISCUSSION
It is well known that the arterial alterations induced by
ESRD include changes in arterial wall thickness due to
rearrangements of the cellular elements and ECM of the
vessel wall.12,13 Although arterial conduit use has become
the standard procedure for CABG, with the concern of the
limited life expectancy of the HD patient with severe
coronary artery disease, the complications of dialysis,
including osteoporosis and coagulation dysfunction,
flow steal during hemodialysis with upper extremity
arteriovenous fistula, and the patients’ poor native
coronary artery conditions, we did not use the left internal
mammary artery conduits as much as we expected during
clinical practice.14 SV conduits can be the more reliable
and available conduits in these cases. The cardiovascularery c September 2012
FIGURE 1. Immunohistochemical evaluation of matrix metallopeptidase (MMP)-2, MMP-9, tissue inhibitor of metallopeptidase (TIMP)-2, and TIMP-3
activity in saphaneous vein (SV) of hemodialysis (HD) and control groups (A–H, DAB staining, original magnification 3100). SVof HD group (n ¼ 15)
showed high expression of MMP-2 and MMP-9 (A and C, respectively). In contrast, in control group (n¼ 19), their expression was low (B and D); TIMP-2
and TIMP-3 immunostaining were notably reduced in SVof HD group (E and G, respectively) compared with those in control group (F and H, respectively).
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Sdamage in HD patients includes a variety of changes in the
vessels.15,16 The vascular changes involve both cellular and
extracellular components. The ECM is a dynamic structure
that requires constant synthesis and degradation by
MMPs. This is tightly controlled by the TIMPs. Therefore,
increased ECM protein synthesis, increased MMP activity,
and decreased TIMP activity might contribute to vascular
ECM deposition and fibrosis. ECM displays a very
dynamic equilibrium in which there is constant synthesis,
degradation, and reorganization.17 Our results revealed
the ECM and adhesion molecule characteristics in the SV
conduits of HD patients. Before being exposed to the in-
creased blood flow and pressure in the arterial system, the
pathologic remodeling of the SV, characterized by ECM de-
position, in HD patients has begun. Furthermore, the Cox
linear regression analysis showed the relationship between
the extent of MMP-2/TIMP-2 imbalance and some impor-
tant preoperative variables. Therefore, if the SV quality re-
vealed by the preoperative profile was poor, the surgical
strategy should be adjusted, and more arterial conduitsThe Journal of Thoracic and Cashould be used, although some limitations and concerns ex-
ist about the use of arterial conduits for CABG in HD
patients.
To determine how the activity of the ECM and adhesion
molecules is altered in SVof HD patients, the gene expres-
sion profile was investigated using microarray analysis. Our
data indicate that some risk factors induced by ESRD in HD
patients deeply influence the biologic properties of ECM
activity in SV conduits. The ECM and adhesion molecule
gene expression profile of the SV conduits in HD patients
showed signs of the vein graft disease process before coro-
nary surgery. Some important ECM and adhesionmolecules
genes, including the MMP/TIMP system and collagen,
showed significantly different activity.
In addition to the increased traditional risk factors, HD
patients could alsohave anumberofnontraditional cardiovas-
cular risk factors thatmight play an important role in the path-
ogenesis of vein graft disease.18,19 Also, the pathogenesis of
cardiovascular damage in HD patients is far more complex
than in the general population. Moreover, this increase inrdiovascular Surgery c Volume 144, Number 3 687
FIGURE 2. Alteration of saphaneous vein (SV) tissue matrix metallopeptidase (MMP)-2, MMP-9, metallopeptidase (TIMP)-2 and TIMP-3 protein levels
induced by end-stage renal disease (ESRD). A, Representative Western blot showing tissue MMP-2, MMP-9, TIMP-2, and TIMP-3 expression in SV sam-
ples of hemodialysis (HD) and control groups. b-Actin was the loading control. B, Densitometric evaluation of MMP-2 expression; C, MMP-9; D, TIMP-2;
and E, TIMP-3.
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the traditional risk factors for cardiovascular disease. The
complex effect of some nontraditional risk factors,
including lipoprotein(a), apolipoprotein A, apolipoprotein
B, homocysteine, calcium, phosphorus, and parathyroid
hormone, on SV conduits of HD patients is not well known.
Our findings also suggest that the extent of MMP-2/TIMP-2
imbalance of SV was directly related to some preoperative
ESRD-related parameters.
The atherosclerotic changes in the carotid arteries mea-
sured by ultrasonography mirror the atherosclerosis of the
coronary arteries in the general population and in HD pa-
tients.20,21 In some studies, a significant increase was
found in the intima-media thickness and plaque occurrence
in the carotid arteries in the HD patients compared with the
age- and gender-matched healthy control subjects.22 In the
present study, a positive correlation between intima-media
thickness and plaque occurrence plaques in the carotid ar-
teries with the extent of MMP-2/TIMP-2 imbalance in the
SV conduits in HD patients was also observed. Therefore,
intima-media thickness and plaque occurrence plaques in688 The Journal of Thoracic and Cardiovascular Surgcarotid arteries could be considered a mirror of the SV con-
dition in HD patients. Because coronary artery calcification
score is a sensitive marker of coronary artery atherosclero-
sis, it would be of interest to determine whether it has a di-
rect relationship with the MMP-2/TIMP-2 imbalance of the
SV in HD patients.23 Our data have shown that coronary ar-
tery calcification score can be viewed as a sign of SV re-
modeling in HD patients. It was observed that increased
lipoprotein(a) and apolipoprotein B levels had significant
correlation with carotid atherosclerosis in HD patients.
Such a significant correlation was also found when SV re-
modeling was considered. Although high apolipoprotein
A, homocysteine, calcium, phosphorus, and parathyroid
hormone levels have been independently associated with
greater rates of cardiovascular disease in patients with
ESRD, the data did not show a direct correlation between
them and SV conduit damage in the HD patients in our
study. The explanation for such unexpected results might
be related to the limited number of patients. Nevertheless,
these findings have demonstrated the importance of careful
monitoring and management for some nontraditional riskery c September 2012
Sun et al Evolving Technology/Basic Sciencefactors in patients with ESRD, particularly if they have un-
dergone CABG. Therefore, the assessment of some nontra-
ditional risk factors in HD patients scheduled to undergo
CABG might offer useful information on conditions of
grafting conduits for coronary surgery.
In conclusion, the results from our study suggest that the
ECM and adhesion molecule gene expression profile of the
SV conduits in HD patients has shown signs of the vein graft
disease process before coronary surgery. Some important
ECM and adhesion molecule genes showed significantly
different activity that was induced by ESRD. Moreover,
these observations raise the question of whether a local ge-
netic anticoagulant treatment should be considered for HD
patients with vein bypass grafts. Novel therapeutic ap-
proaches could develop that transform the SV conduit into
a vessel with increased long-term patency.24 This question,
however, remains to be answered by appropriately designed
clinical trials.E
T
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SStudy Limitations
Several limitations of the present study have to be ad-
dressed. First, the study focused on the native pathologic re-
modeling of the SV in HD patients. However, surgical
manipulation could affect SV graft integrity and might
promote neointima characterized by ECM deposition,
which need to be investigated. Second, although there
were significantly different ECM and adhesion molecule
gene activities between the HD and normal SV conduits,
the numbers of specimens was still too small to reach the
definitive conclusion. Third, although the microarray dem-
onstrated the expression files of 84 ECM and adhesion
molecule-focused genes, techniques with greater sensitivity
and more detailed profiles to investigate the pathologic re-
modeling of SV characterized by the ECM deposition still
need to be found.References
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